Defensive Biotech Champion with Future Potential!
Compared to many smaller biotechs, Amgen has historically shown low price volatility.
Especially in oncology, new therapies could accelerate growth again and push the stock to new all-time highs.
Reading Time: 2 minutes
The Amgen stock (NASDAQ: AMGN) is, in my view, a defensive biotech giant with remarkable stability. The company is represented in the Dow Jones Industrial Average, S&P 500, and Nasdaq 100 and has an exceptionally robust operational base: 14 blockbuster drugs, each generating over $1 billion in annual revenue, provide predictable cash flows and broad diversification. Particularly impressive is the capital discipline: For 15 years, the dividend has been increased every year. This is a strong signal of reliability and shareholder focus. At...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
